Cheap Stocks, 3/30/12 Update

A good week for us again. We were up 2.8% last week and are now up 28.1% for the year.

Some of our stocks are just stupid cheap—compared to their net cash on hand. Check this list:

Cash as % of Stock Price:

RIMG 71%
EXTR 41%
PTIX 43%
GRVY 74%
CCUR 85%
MTSL 38%
SIGM 90%
ASTX 74%
CTIG 87%
MRVC 46%
ANGN 42%

Plus EXTR, RIMG, ANGN and MRVC.PK are all in “play” with activist shareholders either trying to get them to pay out special dividends or take them over, or they are pursuing “strategic alternatives”.

The DOW was up 1.0% last week, NASDAQ was up .80% and the S+P 500 was up .80%. The Russell 3000 was up .70%.

AVNW, CBEY, MTSL, and MITL are our favorites.

AEZS, CTIG and GRVY earnings last week.

For the year, the DOW is up 8.1%, NASDAQ is up 18.7%, S+P 500 is up 12%, and the Russell 3000 is up 12.3%

Last week we went 10 stocks up, 11 down and 3 unchanged. Since inception we are now 58 stocks up and 15 down for a 79.5% winning percentage (80% is our target win %).

Since our beginning, we have closed out the following positions:

2006-NTCT +44%
2006-ONXS +11% (Buyout offer)
2006-DTLK +41%
2006-CAW +21% (Buyout offer)
2007-IYXI.ob +44% (Buyout offer)
2007-MOBI +47% (Buyout offer)
2007-INFT +11% (Buyout offer)
2007-RITT +62%
2007-MIVA +55%
2007-DTLK +25% (2 weeks)
2007-PDLI + 3%
2007-QADI +25%
2007-CIMT +50%
2007-BDR +19%
2007-LINN.ob -57% (mortgage business bust didn’t help here)
2007-TISA -39% (take some tax loss for 2007 due to disappointing results.
2008-ANGN +26%
2008-OPTO.ob +40% (Buy-out offer)
2008-PDLI +9% (company split, and special dividend)
2008-BDAY -39% (long overdue takeover offer-or “take-under”)
2008-DTLK +40% (third trip on this one)
2008-ILOG +26% (Buy-out offer from IBM)
2008-PARL +56%
2009-MBRK +67%
2009-SNWL +14%
2009-CYNO +25%
2009-DTLK +33%
2009-NED +46%
2009-CUTR +13%
2009-HSTM +67% (continued good earnings)
2009-RNWK +36%
2009-OPK +116%
2009-CLZR -32% (a loser even on a buy-out)
2009-DTLK +28% (our 5th profitable trip on this one)
2010-HPOL +110%
2010-DIVX +25%
2010-CHRD +37% Buyout (2 weeks after we recommended it)
2010-HPOL +30%
2010-MGIC +82%
2010-GSL +78%
2010-CCEL +49%
2010-HPOL +27%
2010-CAW EVEN (excluding 2.5 years of dividends)
2011-DWCH +116%
2011-IPAS +15%
2011-PRM +56% Buyout (1 week after we recommended it)
2011-RST +12%
2011-NINE -10%
2012-BVSN +30%

The model portfolio assumes $10,000 invested in each stock (unless we double-up–then it is $20,000), less $10 commission each way (TD Ameritrade rate).

For the 49 stocks that we closed out since 2006 (44 were winners) the average net gain was 37%.

Aviat Networks Inc. (NASDAQ-AVNW)-Recommended 2/27/2012)
Buy Price- $2.62
Valuation $8.31
Closed down $.18 at $2.92
Up 8%, BUY

CBeyond Inc. (NASDAQ-CBEY)-Recommended 2/28/2012)
Buy Price- $7.94
Valuation $29.21
Closed down $.16 at $8.00
UP 1%, BUY

Top Image Systems. (NASDAQ-TISA)-Recommended 12/7/2011)
Buy Price-$2.03
Valuation $4.98 (Was $4.89)
Closed unchanged at $4.10
TISA is officially discovered and we have a double.
Earnings announced in March. Another good quarter. Revenue rose 25% to $7.3 million and they made $.04 per share compared to a $.09 loss last year. For the year they made $.23 per share. Their guidance for 2012 was great. Revenues expected to rise approximately 20% and it looks like $.35 per share in EPS is possible. Our valuation rose slightly to $4.98.
TISA announced a $2 million order to do the Italian census in January. Good news just keeps coming here.
TISA published a letter to shareholders in January, noting all the positives about the company and stating that they still believe the shares are still undervalued.
Up 102%, HOLD

MRV Communications (Pink Sheets-MRVC.pk)
Valuation $2.36 (Was $2.46 (after $.0475 special dividend), $2.92, $3.09)
Buy Price October 7, 2011- $.80 ($1.27 before special dividend)
Closed up $.01 at $1.05
MRV closed their sale of CES last week. Another $24 million added to the cash pot. Cash should be about $.60 a share now.
Earnings announced in March. Sales were up slightly to $74.1 million from $73.5 million last year. They lost $6.5 million but this was after a $7.1 million goodwill write off and about $2 million of special charges. Net cash stood at about $76 million or $.48 per share. Our valuation fell a bit to $2.36—still more than double the current stock price.
Raging Capital bought more than 1.3 million more shares in March at $1.03.
CFO and VP of Finance has resigned and gotten lucrative “stay” bonuses if they stay through March 31, 2012 and get the 10K filed. We think the “stay” bonus is really to get the company sold by then.
Up 19% HOLD

Sigma Designs Inc. (NASDAQ-SIGM)-Recommended 7/11/2011)
Buy Price-$8.49
Valuation $8.41 (Was $12.10, $13.40, $16.02)
Closed down $.29 at $5.18
Potomac Capital filed a 13D/A last week as they raised their stake in SIGM to 5.7% with purchases around $5.50 of about 140,000 shares. Stock still fell.
“Earnings” announced in March. Not good. Revenues down 50% from last year and down 10% from the previous quarter. They lost $18 million $.58 per share ($14 million non-GAAP loss) for the quarter. Cash was $150 million or $4.60 per share but down $1.06 per share for the year. They are saying they expect to reach profitability and cash flow positive operations by the end of this fiscal year (January 2013). Our valuation plunged to $8.41 per share.
Mak Capital One LLC filed a 13G in November disclosing a 6.6% (2,110,000 shares) stake in SIGM.
So we are trading at a market cap of about $20 million (excluding cash) for a $150- $200 million a year chip company with 50% margins. Still pretty stupid we think. With the falling valuation we are thinking of selling, but will hold on for another couple of quarters to see if they can turn this around.
Down 39%, Weak-HOLD

Mitel Networks (NASDAQ-MITL)-Recommended 7/6/2011)
Buy Price- $3.04( Was $3.36 before $10,000 added, $3.95 before $10,000 added)
Valuation $12.81 (Was $15.28, $14.04, $10.39)
Closed up $.40 at $4.29.
Earnings announced in March. Revenues from continuing operations were up 5% to $150 million and they made a profit of $.08 on a GAAP basis and $.22 a share on a non-GAAP basis. MITL is selling it’s DataNet/CommSource units which contributed about $14 million in sales during the quarter but are not included in their sales figures and therefore our valuation. Due to this reclassification to “discontinued operations” our valuation fell to $12.81 per share, still more than 3 times its current trading price. Overall we think this is a great earnings report, and this is a buying opportunity.
Up 41%, BUY

Rimage (NASDAQ-RIMG)-Recommended 5/24/2011)
Buy Price-$14.20
Valuation $$19.81 (Was $22.23, $25.63, $26.45)
Closed down $.23 at $10.01
Pays $.68 a share annual dividend.
Earnings announced in February. Hmmm. Sales fell from $24.7 million to $21.7 million and they were breakeven on a Non-GAAP basis with a reported loss of $.13 per share. Cash fell to $70 million or $6.87 per share as they spent $2 million on share buybacks and our overall valuation fell to $19.61.
Guidance for 2012 is low double digit sales growth and the same level cash flow. They also declared their $.17 quarterly dividend. Teetering on selling here despite the yield.
Down 30%, HOLD

Lexmark International (NYSE-LXK)-Recommended 5/24/2011)
Buy Price-$28.80
Valuation $67.94 (Was $63.84, $79.12, $63.99)
Closed down $1.04 at $33.24
Pays $1.00 per share annual dividend.
Earnings announced in February. Good as expected. Revenues were $1.06 billion and they made $1.25 per share on a Non-GAAP basis. They ended the year with $6.91 per share in net cash and our valuation rose to $67.94. They repurchased 7.9 million shares over the last couple of quarters and ended up with 74 million fully diluted shares used in the EPS calculation in Q4. They reiterated their intent to return over 50% of their free cash flow to shareholders in dividends and share repurchases and then they announced another $30 million (730,000 share) repurchase on Friday. They have just over $200 million left on their stock repurchase authorization.
This would normally be a “buy” with such a huge discount to our valuation, but the vagaries on the stock analysts make us cautious.
Up 15%, HOLD

MER Telemanagement (NASDAQ-MTSL)-Recommended 5/17/2011)
Buy Price-$1.42 (Was $1.50 before adding another $10,000 investment)
Valuation $6.28 (Was $5.61, $5.11)
Closed up $.03 at $2.00
Earnings announced in March. Not bad. Sales were up YOY to about $3.2 million from $3 million. They reported a loss of $201,000 ($.05 per share) compared to income of $117,000 ($.03 per share) last year, but the results were due to a large patent litigation settlement expense. They did not disclose the amount for the quarter, but these litigation expenses were $640,000 for the year. Net cash rose to $.77 per share.
Up 41% HOLD

Harris Interactive (NASDAQ-HPOL)-Recommended 3/3/2010)
Buy Price-$.92
Valuation $3.05 (Was $2.90, $3.11, $2.63, $2.97)
Closed at $1.33, up $.16
EVP purchased 12,500 shares in March at $1.03 and interim CFO bought 11,000 shares at $1.02.
HPOL’s new, “permanent” CEO is already in action. They announced in early March a $3 million share buy back program and forecast that adjusted EBITDA for 2012 would increase about 54% from 2011 and that they believe their shares are undervalued. We do too.
Earnings announced in February. Things are looking up! Although revenues were down from $45 million last year to $39 million, operating income more than doubled to $2.1 million from $.9 million and net income rose to $1.6 million from $.3 million last year. Net cash also rose to over $5 million or $.10 per share. Our valuation jumped to $3.05.
Up 45%, HOLD

Concurrent Computer (NASDAQ-CCUR)-Recommended 2/4/2011)
Buy Price-$5.08
Valuation $14.13 (was $11.38, $14.04, $18.54, $15.99)
Closed up $.04 at $3.64
Earnings announced in February. Better than the previous quarter for sure, but just ok. Sales were down from $17.9 million last year to $16.4 million, but well above the $12.9 in Q3. They lost $833,000 compared to $1,189,000 last year and $2.6 million in Q3. Cash fell from $3.50 to $3.10 per share as receivables increased by $3.2 million ($.37 per share). Overall our valuation rose to $14.13.
Down 28%, HOLD

Astex Pharmaceuticals Inc. (Was SuperGen Inc.) (NASDAQ-ASTX)-Recommended 10/4/2010)
Buy Price-$2.31 (was $2.09 before adding $10,000)
Valuation $3.42 (was $3.22, $3.11, $5.21, $4.89, $4.37, $3.48)
Closed up $.12 at $1.86
Earnings were announced in March. Not bad. Revenue for the year was just over $66 million and they made $5.5 million in net income. Cash was $1.37 a share. Our valuation fell to $3.22 a share on the negative effects of the merger on net income.
Projections for next year are for revenues to rise by about 10% and a net loss of $13-$15 million of which about $10 million appear to be non-cash charges.
So we have a company losing maybe $5 million in cash a year, or 25 years of cash, about $70 million in revenues and a huge drug pipeline. Any good news on the clinical trials front ought to set this stock on fire.
As we said before, the merger with the revenue poor Astex hurt our valuation which does not take into account the massive drug pipeline of Astex. It is not easy to find a small drug company that has a pile of cash, is not losing a ton of money and is trading at even close to our valuation.
There are $2 BILLION of potential milestone payments down the road.
Down 19%, BUY

Performance Technology (PTIX-Recommended 3/30/2010)
Buy Price-$2.70
Valuation $6.17-(was $5.94, $4.87, $4.99, $3.79, $3.87, $5.03, $5.98, $7.13)
Closed up $.28 at $2.58
Earnings announced in March. Sales rose 34% to $9.1 million and they made a profit! $473,000 or $.04 per share. On a Non-GAAP basis they made $1 million or $.09 per share. Cash stayed level at $1.12 per share and our valuation rose to $6.17.
Down 4%, BUY

Extreme Networks (EXTR-Recommended 3/22/2010)
Buy Price-$3.18 (Was $3.04 before adding another $10,000)
Valuation-$7.01 (was $6.72, $6.45, $5.67, $7.36, $7.23, $7.31, $6.82, $6.81)
Closed down $.10 at $3.83
Earnings announced in February. Revenues dropped a tad from $85 million last year to $83 million and they made $5.8 million of net income on a Non-GAAP basis versus $5.1 million last year. Cash per share rose to $1.56 per share from $1.50 and our valuation rose to $7.01 per share. The company also announced last week that they have sold an option to a possible buyer of their corporate headquarters in California for $48.5 million. The option lasts until the end of 2012. That would add another $.50 a share (pre-closing costs and taxes) to the cash till.
Starboard owns 9.7%, Soros 8.8% and Blackrock owns 5.5% of EXTR.
Up 21%, BUY

Gravity Company Ltd. (GRVY-Recommended 1/18/2010)
Buy Price- $1.45 per ADS (Was $1.68 before double up)
Valuation $5.39-(Was $5.33, $5.61, $5.73, $4.38, $4.44, $5.15)
Closed down $.19 at $2.75
Ragnarok was commercially released in Korea on March 26th. Non-consolidated earnings were filed with the SEC last week also. A bit of confusion here as previous filings/announcements were on a consolidated basis. So we will wait for some clarification here before we revise our valuation. A perusal of the non-consolidated results seem consistent with previous consolidated results with cash of about $40 million, net income of about $13 million and sales of about $34 million.
Earnings announced in November. Not bad at all. Revenues rose 8% to $13.4 million and they made $3.1 million or $.11 per ADS. For the nine months ended September 30th, they have made $.25 per ADS. Cash fell about $1.5 million to $2.05 per ADS.
Our valuation rose a bit to $5.39.
Up 89%, HOLD

AEterna Zentaris (AEZS-Recommended 6/20/2009)
Buy price $1.42 (was $1.78 before adding another $10,000, $1.82 before double up)
Valuation –Speculation.
Closed up $.19 at $2.14
Earnings out in March. Revenues for the quarter were $12.6 million, up from $10 million last year. Net loss was $7.5 million compared to $6.6 million last year. The net loss for the year was $29 million. Cash stood at $47 million and they continue to sell more stock. They sold another 3.6 million in 2012 so far and raised $6.4 million.
Speculative for sure.
Up 50%, HOLD

Spectranetics (SPNC-Recommended 9/2/2006)
Buy price $5.68 (was $8.90, $9.40 before adding $10,000, and was $10.65 before double up),
Valuation –$13.00 (was $12, $10)
Closed down $.13 at $10.40
Piper Jaffray put a price target of $13 on SPNC. Lots of insider buying too—after years of no buying.
Earnings announced in February. Revenues were up 11% and they made $.04 on a non-GAAP basis (lost $.06 on a GAAP basis after the litigation charge and license termination charge). Cash rose to $39 million, gross margins improved a bit also. Guidance for 2012 is a 5-7% increase in revenues and $.04-$.08 in earnings per share, excluding two new product introductions anticipated for mid year introductions.
.This company needs to be sold so that someone can take advantage of their 70%+ gross margins and enjoy some profits.
Paragon filed a 13D/A in May 2011 disclosing they had upped their stake to 7%.
Up 83%, HOLD

Mediware (MEDW-Recommended 6/4/2007)
Buy Price $6.33, (was $6.52, $6.67 ($10,000 added), $6.98 after double up)
Valuation $18.15 (was $17.96, $18.34, $16.07, $15.04, $14.23, $15.02, $14.35, $12.13, $12.57, $12.29, $11.90, $11.30, $11.48, $11.47 $10.99, $10.28, $13.32, $12.89, $13.40)
Closed down $.21 at $14.69
MEDW announced another small acquisition in March. They are paying $2.2 million for a cancer management software line.
Earnings announced in February. Another good report. Sales were up 18%, pre-tax income was up 30%, but due to a higher tax rate EPS was flat at $.21 per share. Cash rose to $4.27 per share and our valuation moved up again to $18.15.
MEDW announced an acquisition in January. The acquired company sells software into the same customers as MEDW but in the adult stem cell and cord blood management area. No financial information about the acquisition or its revenues was disclosed. Looks like another growth area for the company. Constellation Software, who owns over 20% of MEDW announced in January that they had concluded their analysis of strategic alternatives. This is the code for they couldn’t find a buyer. Good company but already overvalued. Maybe they will turn their attention back to acquiring MEDW? We can dream.
All we read is that medical records will be a hot area, so MEDW looks like the place to be.
Up 132%, HOLD

Inuvo (INUV (was-VTRO, MIVA)-Recommended 10/21/2007)
Buy Price $8.15 (Was $11.90 before adding another $20,000, $13.10 before another $10,000 and was $15.00 before double up),
Valuation $8.04 (was $10.91, $12.42, $14.23, $14.76, $12.40, $12.55, $10.85, $8.25, $9.45, $28.05, $32.10, $34.20, $37.90, $37.95)
Closed at $.77 down $.11
The Inuvo/VTRO merger closed in March and we now have 1.546 shares of INUV for each VTRO share we had before. We will wait a bit to see it .5 plus .5 can make 2.
They expect merger cost savings to be more than $2.4 million a year.
Should have sold this when it traded over $6.
Down 85% HOLD

Angeion Corporation (ANGN-Recommended 8/28/2008)
Buy Price-$3.82 (was $5.15 before $10,000 added)
Valuation $13.36 (was $15.90, $13.13, $13.19, $13.60, $15.00, $13.06, $12.15, $11.29, $11.73, $11.47, $11.16, $9.53, $13.30, $13.03)
Closed down $.33 at $5.74
Earnings announced in March. Ok, but certainly not great. Revenues were flat at $7.1 million and they lost $249,000 or $.07 per share, slightly better than last years $.09 per share loss. Cash rose slightly to $2.42 per share and our valuation fell to $13.36 compared to $13.60 in the same quarter last year.
Angeion disclosed in an SEC filing in December that they had retained an investment banker to look at “strategic alternatives” that may also involve the sale of its New Leaf product line. Company could be for sale, or just a part of it. In any event this should be good news for us shareholders and ANGN continues to be significantly undervalued.
CEO bought 10,000 shares in September at $4.25. Good sign.
If this company could just show a bit of growth I think we would see $10 in short order—if.
Blueline Partners still owns 7.6% of ANGN and ought to be pushing on the company to do something about the stock price.
While ANGN is still trading at less than ½ our valuation, we are switching to a HOLD until we gets some results or news that improves the prospects here.
Up 50%, HOLD

OB-abies (Bulletin Board Listed Stocks)

As proven by OPTIO, patience is necessary with these stocks.

ARI Networks (ARIS.ob-Recommended 8/19/2006)
Buy price $1.61 (Was $1.78 before another $10,000 added, was $2.06 before double up),
Valuation $5.82 (was $5.81, $5.72, $5.65, $5.39, $4,86, $5.60, $5.73, $5.54, $5.74, $5.96, $4.72, $5.19, $5.66, $5.63, $5.61, $5.71, $5.49, $5.34, $5.03, $5.28, $5.28, $5.21)
Closed at $1.75 up $.20.
Earnings announced in March. Not bad. Sales were up to $5.5 million from $5.2 million last year. They only made $61,000 ($.01) of income versus last years $123,000 ($.02). Their net cash position improved a tad to minus $3.7 million from minus $3.8 million last year. Our valuation stayed about the same at $5.82.
ARI announced a reseller win in February in addition to one in January for a 160 dealer outfit.
Now up 9%, BUY, Still a Huge valuation gap here.

Rand Worldwide (RWWI.ob (Was Avatech, AVSO.ob)-Bought November 28, 2005)
Buy price $.79 (Was $.93, $.99 and $1.19 before adding $10,000-each time),
Valuation $2.08 (was $2.09, $2.12, $2.60, $2.40, $1.90, $2.26 $3.07, $3.03, $2.38, $2.57, $2.81, $2.78, $3.30, $3.76, $4.00 $3.41, $3.05, $2.53, $3.25, $3.29 $2.69, $3.36, $3.81)
Stock closed at $.80, up $.13
Peter Kamin the new Chairman of the Board filed a 13d in March disclosing an 11% ownership state. Interesting as one would file a 13G if their intention was to just be a passive investor. Maybe as Chairman he will do SOMETHING to get the share price up.
RWWI announced an acquisition in March, but gave no financial details. “If a tree falls in the forest but there is no one around to hear it, dies it make a sound”? Seems like the company is making no effort to get this company known to the investment community. We have been in this one a LONG time and are getting impatient.
Earnings announced in February. Decent. Sales were $22.5 million up from $21.7 million last year, gross margin was 47% and they made $1 million or $.02 per share. Our valuation dropped $.01 to $2.08 as there were 3 million more fully diluted shares outstanding. Cash was still a net negative, but getting close to even. Market cap of $34 million for an $80 million in sales company with almost 50% margins and not losing money, just too cheap.
Still more than 2X the current price.
Up 1%, HOLD

CTI Holdings (CTIG.ob-Recommended 2/25/2006)
Buy price $.27 ask,
NEW Valuation $1.36 (Was $1.37, $1.23, $.91, $1.21, $.71, $.83, $.88 $.96, $.93, $.75, $.85, $1.57, $1.40, $1.29, $1.38, $1.31, $1.38, $1.29, $1.42, $1.28 $1.13, $1.05, $.82)
Ask price $.117, closed at $.11.
Earnings last week. Sales were up $100k over last quarter to $4.5 million and they made $160k. Cash fell to $2.9 million or $.10 per share. Our valuation fell a penny to $1.36. Two profitable quarters in a row. The CEO expressed confidence that they can continue to grow revenues in the press release.
CEO reported another 44,000 of stock purchases in late 2011 at $.095 to $.10 per share.
At a $2.6 million market cap, this is stupidly cheap. Their intellectual property is probably worth 10 times this price. They need to liquefy this value somehow.
Still an “undercover” company and stock.
Down 57%. BUY

Lotus Pharmaceuticals (LTUS.ob-Recommended 12/3/2007)
Buy price $1.68 (Was $1.80 before $10,000 adder, $2.16 before double-up)
Valuation-$.85 (Was $1.05, $2.43, $4.11, $4.84, $4.98, $4.60, $3.82, $4.00, $3.68, $3.12, $3.98, $4.44, $3.22, $2.12, $4.56, $4.16)
Closed at $.20, unchanged
Oiy! Lotus announced in January that they had “sold” their Mongolian land. They get nothing for it and give up 3 drugstores in Bejing and $7 million of receivables. Not good as reflected on the huge (percentage wise at least) drop in the stock. This has indeed become a cheap lottery ticket. 5 shares for a buck. We are licking our wounds on this one, but will just wait it out. It may go to $0, or may hang around in the penny stock range for a while. The move into the new building has commenced and the warehouse (supposedly critical to selling in Bejing) will be functional by March and production to start by September.
Earnings announced in November. Revenues were up slightly over last year at $19 million versus $18.3 last year, but gross margins remained low and they made $2.1 million of $.04 per share compared to $.25 last year. Our valuation fell again to $.85.
Down 88%, HOLD

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s